Nevertheless, screening for prostate cancer using a prostate specific antigen (PSA) test remains a controversial issue; implying a trade-off between benefits (mortality reduction, early diagnosis) and risks (high instances of overdiagnosis and overtreatment in conjunction with the consequent side effects, as well as false positive and false negative test results) [2, 3]. This evidence concerns the gene KLK3 and Familial prostate cancer.